Migraine – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2021 To 2032


 Migraine is a type of headache that causes severe throbbing or pulsing pain on one side of the head. It's often accompanied by nausea, vomiting, and extreme light and sound sensitivity. Migraine attacks can last anywhere from hours to days, and the pain can be severe enough to prevent you from going about your daily activities. It is likely to be a brain disorder involving altered regulation and control of afferents, with a particular focus on the cranium. Migraine is a sensory processing disturbance with broad ramifications for central nervous system function. While pain is used as the exemplar symptom, a brain-centered explanation provides a framework for understanding all the manifestations of migraine. For some people, a warning symptom known as an aura occurs before or with the headache. An aura can include visual disturbances, such as flashes of light or blind spots, or other disorders, such as tingling on one side of the face or in an arm or leg and difficulty speaking. Migraines, affecting children, teenagers, and adults, can progress through four stages: prodrome, aura, attack, and post-drome. Not everyone who has migraines goes through all stages.

 

The prevalence and burden of self-reported migraine and severe headaches in the US adult population is high, affecting roughly 1 out of every 6 American and 1 in 5 women, 9.7% of males and 20.7% of females are being diagnosed.

 

The competitive landscape of Migraine includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Migraine across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Migraine Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Migraine – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          Zavegepant (BHV3500) Biohaven Pharmaceuticals, Inc. Phase 3

2          Erenumab         Amgen  Phase 3

3          Lasmiditan        CoLucid Pharmaceuticals          Phase 3

4          ZNS      Impax Laboratories, LLC            Phase 3

5          ABP-450           AEON Biopharma, Inc.  Phase 2

6          Eptinezumab     Alder Biopharmaceuticals, Inc.   Phase 3

7          Telcagepant      Merck Sharp & Dohme LLC       Phase 3

8          M207    Zosano Pharma Corporation      Phase 3

9          Ubrogepant       Allergan            Phase 3

10        AXS-07 Axsome Therapeutics, Inc.         Phase 3

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more